The NATAN study showed that zoledronic acid doesn’t work in that average woman in this trial [one with early breast cancer, residual tumor remaining after neoadjuvant therapy]. There is, however, a trend to modest benefit in women older than 55, which is consistent with statistically significant benefit seen in a meta-analysis for bisphosphonates in adjuvant therapy trials, as was shown by the meta-analysis presented here,” stated Peter Ravdin, MD, of San Antonio, Texas.
Dr. Ravdin believes that the National Comprehensive Cancer Network will consider the findings of the Oxford meta-analysis and possibly include bisphosphonates as adjuvant therapy for postmenopausal women. ■
Disclosure: Dr. Ravdin reported no potential conflicts of interest.
Zoledronic acid does not improve outcomes in patients with early breast cancer who do not have a full response to neoadjuvant anthracycline/taxane–based chemotherapy, according to results of the Neo-Adjuvant Trial Add-On (NATAN) study presented at the 2013 San Antonio Breast Cancer Symposium.1 A...